[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-interstitial-cystitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-interstitial-cystitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,77,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100450751","investigation-of-pemf-therapy-for-female-patients-with-icbps-100450751",false,"NCT05149573","Investigation of PEMF Therapy for Female Patients With IC\u002FBPS","Investigation of Non-Invasive Pulsed Electromagnetic Field (PEMF) Therapy for Female Patients With Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS)","Inclusion Criteria:\n\n* Previously established clinical diagnosis of IC\u002FPS\n* Current numeric rating scale (NRS) score of ≥ 6\n* History of cystoscopy with hydrodistension with bladder capacity determination under anesthesia\n* No cognitive deficits\n\nExclusion Criteria:\n\n* History of bladder, ovarian, vaginal cancer\n* History of urethral diverticulum\n* History of radiation cystitis\n* History of spinal cord injury or spina bifida\n* History of Parkinson's disease, multiple sclerosis, or stroke\n* Current placement of a pacemaker or metal prosthesis\n* Active urinary tract infection\n* BMI \\> 40\n* Residual urine of \\> 100cc\n* Current pregnant","FEMALE","18 Years","80 Years",{"count":20,"type":21},75,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to gather information about the safety and effectiveness of the non-pharmacological (non-drug), non-invasive treatment known as low-frequency pulsed electromagnetic field (PEMF) therapy. The study team will distribute the PEMF device to female adults with Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS) to measure its ability to decrease bladder and pelvic pain as well as other urinary symptoms associated with IC\u002FBPS. There are two sequential Aims in this study and subjects will be recruited to participate in only one Aim. In both Aims, data will be collected at baseline\u002Fenrollment, 4-weeks after using PEMF therapy, and 8, 12, and 16 weeks post-enrollment.",[27,28,29],"Interstitial Cystitis","Chronic Interstitial Cystitis","Bladder Pain Syndrome",[31,32,33,34,35,36,37,38],"interstitial cystitis","bladder pain syndrome","painful bladder syndrome","painful bladder","bladder pain","urinary urgency","urinary frequency","pulsed electromagnetic field","RECRUITING","2026-05-06",{"date":42,"type":43},"2026-05-07","ACTUAL",{"date":45,"type":43},"2022-08-29",{"date":47,"type":21},"2027-02",{"name":49,"class":50},"Wake Forest University Health Sciences","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":51},"100517123","efficacy-of-pulsed-electromagnetic-field-and-heparinbupivacaine-instillations-100517123","NCT06013449","Efficacy of Pulsed Electromagnetic Field and Heparin\u002FBupivacaine Instillations","Investigation of the Effect of Simultaneous Pulsed Electromagnetic Field (PEMF) and Intravesical Heparin - Bupivacaine Cocktail Instillation for the Symptomatic Treatment of Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS)","Inclusion Criteria:\n\n* Previously established clinical diagnosis of Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS)\n* Current Numeric Rating Scale (NRS) greater than or equal to 5\n* History of cystoscopy with hydrodistension with bladder capacity determination under anesthesia\n* No contraindications to the instillation solution\n* No cognitive deficits\n\nExclusion Criteria:\n\n* History of bladder, ovarian or vaginal cancer\n* History of urethral diverticulum\n* History of radiation cystitis\n* History of spinal cord injury or spina bifida\n* History of Parkinson's Disease\n* History of Multiple Sclerosis (MS)\n* History of Stroke\n* History of genital herpes\n* History of or current cyclophosphamide treatment\n* Current placement of a pacemaker or metal prothesis\n* Active urinary tract infection\n* BMI \\>40\n* Residual urine of \\>100 cc\n* Currently pregnant",{"count":60,"type":21},20,[24],"The objective of this study is to test the idea that Pulsed Electromagnetic Field (PEMF) therapy will serve as a safe therapeutic modality that can effectively be administered simultaneously with bladder instillations of a bupivacaine-heparin cocktail to improve the chronic pain and\u002For associated symptoms of Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS) patients. The study team will distribute the PEMF device to female adults with IC\u002FBPS who have been prescribed bladder instillations of bupivacaine-heparin to see if PEMF therapy in conjunction with bladder instillations of heparin and bupivacaine may be more effective in reducing pain levels and symptomatology of IC\u002FBPS than instillations alone.",[27,28,29],[31,32,34,65,36,37,38,66,67],"chronic pelvic pain","PEMF","bladder instillation","NOT_YET_RECRUITING","2026-03-30",{"date":71,"type":43},"2026-03-31",{"date":73,"type":21},"2026-09",{"date":75,"type":21},"2027-12",{"name":49,"class":50},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":84,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":98,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":51},"100539118","pain-type-and-interstitial-cystitisbladder-pain-syndrome-treatment-100539118","NCT06299683","Pain Type and Interstitial Cystitis\u002FBladder Pain Syndrome Treatment","Mechanistic-Based Treatment of Interstitial Cystitis\u002FBladder Pain Syndrome","Inclusion Criteria:\n\n* 18 years of age or older;\n* Diagnosis of IC\u002FBPS as indicated by structured assessments;\n* Capable of giving written informed consent;\n* Able to enroll for the duration of the study period;\n\nExclusion Criteria:\n\n* Comorbid neurological conditions including spinal cord injury or systematic neurologic illnesses, or central nervous system diseases such as brain tumor or stroke;\n* Current or history of diagnosis of primary psychotic or major thought disorder within the past five years;\n* Hospitalization for psychiatric reasons other than suicidal ideation, homicidal ideation, and\u002For PTSD (within the past 5 years);\n* Psychiatric or behavioral conditions in which symptoms are unstable or severe (e.g. current delirium, mania, psychosis, active suicidal ideation, homicidal ideation, substance abuse dependency) reported within the past six months;\n* Non-English speaking;\n* Presenting symptoms at time of screening that would interfere with participation, specifically active suicidal ideation with intent to harm oneself or active delusional or psychotic thinking;\n* Difficulties or limitations communicating over the telephone or via teleconferencing systems;\n* Any planned life events that would interfere with participating in the key elements of the study;\n* Any major active medical issues that could preclude participation;\n* Currently pregnant;\n* Currently being treated for cancer;\n* Cancer-related pain;\n* Recently or actively participating in treatment similar to those being investigated (e.g. individual psychotherapy or pelvic floor pt).","ALL",{"count":86,"type":21},220,[24],"Interstitial cystitis\u002Fbladder pain syndrome (IC\u002FBPS) is a severe pain condition affecting 3-8 million people in the United States lacking treatments that work. Emotional suffering is common in IC\u002FBPS and known to make physical symptoms worse, and studies show patient sub-groups respond differently to treatment. Individuals with IC\u002FBPS have distinct subgroups, or \"phenotypes,\" largely characterized by the distribution of pain throughout the body. Supported by our preliminary evidence, the overall goal of this project is to assess how IC\u002FBPS phenotype may affect response to two different therapies often given without regard to patient phenotype, pelvic floor physical therapy (PT) and cognitive-behavioral therapy (CBT) for IC\u002FBPS.",[28,29,90,91,92,27,93,94,95,96,97],"Painful Bladder Syndrome","Cystitis, Interstitial","Cystitis, Chronic Interstitial","Interstitial Cystitis, Chronic","Interstitial Cystitis (Chronic) With Hematuria","Interstitial Cystitis (Chronic) Without Hematuria","Chronic Prostatitis","Chronic Prostatitis With Chronic Pelvic Pain Syndrome",[31,32,99,100,101,102,103,104,105,106,107],"clinical trial","psychosocial intervention","pelvic pain","therapy","urological chronic pelvic pain syndrome","chronic prostatitis","self-management","cognitive behavioral therapy","pelvic floor physical therapy","2026-01-20",{"date":110,"type":43},"2026-01-21",{"date":112,"type":43},"2024-05-01",{"date":114,"type":21},"2028-04-04",{"name":116,"class":50},"Vanderbilt University Medical Center",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":84,"minAge":17,"maxAge":18,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":128,"conditions":129,"keywords":130,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":51},"100418852","early-phase-1-safety-and-efficacy-of-aloe-vera-in-the-management-of-the-symptoms-of-interstitial-cystitis-100418852","NCT04734106","Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis","A Double-Blind, Placebo-Controlled Study to Establish the Safety and Efficacy of Super-Concentrated, Freeze-Dried Aloe Vera in the Management of the Symptoms of Interstitial Cystitis","Inclusion Criteria:\n\n* Females or males, aged 18 years or older\n* Females of childbearing potential must agree to use acceptable methods of birth control. Acceptable methods are oral and injectable preparations, double barrier, vasectomized partner, or abstinence.\n* Participant must sign and date the informed consent.\n* Participant must report a urinary frequency of at least 11 times per 24-hour day, on average over the previous four weeks.\n* Participant must report a pain\u002Fdiscomfort score of 4 or greater on a 0-9 Likert scale.\n* These reported urinary symptoms of frequency and pain\u002Fdiscomfort must have been present for at least the previous 24 weeks prior to the first baseline screening visit.\n* Participants must report in the baseline voiding diary at least one voided volume greater than or equal to 75cc in a 24-hour period.\n\nExclusion Criteria:\n\n* Known allergy or intolerance to aloe vera in any form as reported by the participant or derived from medical records.\n* History of Bladder tumors (malignant or benign).\n* Current active bladder or urethral calculus.\n* History of urethral cancer within the previous five years.\n* Any disease which, in the opinion of the investigator, may be unstable or have bearing on the outcome of the study, including severe debilitating concurrent medical conditions such as coronary artery disease, azotemia, moderate to severe hepatic insufficiency, etc.\n* Previous treatment with Cytoxan (cyclophosphamide).\n* History of cyclophosphamide or chemical cystitis or tuberculosis or radiation cystitis.\n* History of pelvic radiation treatment, bladder cancer or cancer in situ, or urethral cancer.\n* History of any other neoplastic process currently requiring systemic, nonprophylactic treatment.\n* History of urethral diverticulum.\n* Inability to void spontaneously.\n* Subjects with interstitial cystitis symptoms alleviated by current therapy regimen.\n* Uncontrolled diabetes mellitus.\n* Previous enrollment in an aloe vera study.\n* Previous use of Desert Harvest super-concentrated, freeze-dried aloe vera capsules.\n* Any imminent change in residence that could compromise compliance.\n* Unlikely to be compliant due to unmanaged medical or psychological problem, including dementia, aphasia, or other deficits of cognition or speech\u002Flanguage function that will interfere with the participant's ability to complete the study.\n* Substance abuse or dependency problem within the past two years for which patient received no treatment.\n\nMale-Specific Exclusion Criteria:\n\n* Males with a history of prostate cancer within the previous five years.\n* Males with a prostatic infection within the previous three months.\n\nFemale-Specific Exclusion Criteria:\n\n* Females with a history of uterine, cervical, or vaginal cancer within the previous five years.\n* Pregnant or lactating females.",{"count":125,"type":21},30,[127],"EARLY_PHASE1","The purpose of this study is to assess the safety and efficacy of super-concentrated, freeze-dried aloe vera capsules for treatment of interstitial cystitis.",[27,28,29],[131,29,132,133,134,135,136],"Interstitial Cystitis (IC)","Urinary urgency","Urinary frequency","Bladder pain","Nocturia","Urinary incontinence","2025-08-26",{"date":139,"type":43},"2025-08-27",{"date":141,"type":43},"2025-02-18",{"date":143,"type":21},"2027-07",{"name":49,"class":50}]